All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

BiTEs, CAR T-Cell Therapy, and ADCs Offer Variety of Lymphoma Treatment Options, But Questions Remain

July 22nd 2022

An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.

ASCT No Longer Suitable for the Majority of Patients with DLBCL

July 22nd 2022

Most patients with diffuse large B-cell lymphoma do not derive significant benefit from treatment with autologous stem cell transplantation and better therapeutic options are currently available for this population.

Zanubrutinib Displays Improved Efficacy Vs Orelabrutinib in Relapsed/Refractory CLL/SLL and MCL

July 22nd 2022

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.

Molecular Testing Continues to Predict Treatment Efficacy in Ovarian Cancer

July 22nd 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of helping patients make informed decisions about their care options and the future role of antibody-drug conjugate targets in the biomarker testing arena.

Brahmer Discusses Influence of 5-Year Nivolumab and Ipilimumab OS Data in Metastatic NSCLC

July 22nd 2022

Julie R. Brahmer, MD, MSc, discusses how data from the CheckMate 227 trial may affect the treatment landscape for NSCLC and notes the quality-of-life outcomes reported with nivolumab and ipilimumab.

FDA Grants Orphan Drug Designation to DSP-0390 for Brain Cancer

July 22nd 2022

The FDA has granted an orphan drug designation to DSP-0390 for the treatment of brain cancer.

CDK4/6 Inhibitors Could Fill Treatment Void for Patients with HR+/HER2- Early Breast Cancer

July 22nd 2022

Joyce O'Shaughnessy, MD, outlines the current role and ongoing research of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative early stage breast cancer.

Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL

July 21st 2022

CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma, according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH.

Pooled Real-World Data Support Earlier Line Use of IRd in Relapsed/Refractory Multiple Myeloma

July 21st 2022

A pooled analysis of the INSIGHT MM, UVEA-IXA, and REMIX observational studies found that real-world outcomes with ixazomib/lenalidomide/dexamethasone were consistent with those reported in the TOURMAILINE-MM1 study.

Increased Treatment Efficacy in p53-Mutated MCL Remains Elusive

July 21st 2022

Tycel Jovelle Phillips, MD, outlines the reasons why p53-mutated mantle cell lymphoma is difficult to treat and discusses potential future directions for the treatment of this subgroup of patients.

Eltanexor Gets FDA Fast Track Status and Orphan Medicinal Product Designation in Europe for MDS

July 21st 2022

Eltanexor has been granted a fast track designation from the FDA and an orphan medicinal product designation from the European Commission for use as a potential therapeutic option in patients with myelodysplastic syndromes.

FDA Grants Fast Track and Rare Pediatric Disease Designations to WU-CART-007 in R/R T-ALL and LBL

July 21st 2022

The FDA has granted fast track and rare pediatric disease designations to the CAR T-cell therapy WU-CART-007 for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

Selinexor Combo Approved in Europe for Multiple Myeloma After at Least 1 Prior Therapy

July 21st 2022

The European Commission granted a full marketing authorization to selinexor in combination with once-weekly bortezomib and low-dose dexamethasone for the treatment of adults with multiple myeloma who have received at least 1 previous therapy.

Multidisciplinary Team Approach Is Ideal for irAE Management in Follicular Lymphoma

July 21st 2022

Immune checkpoint inhibitor therapy in relapsed follicular lymphoma can induce immune-related adverse events which can be difficult to diagnose and manage.

Adding Novel Agents to Established Chemotherapy Regimens Key to Expanding Frontline Treatment of Classic Hodgkin Lymphoma

July 21st 2022

Alison J. Moskowitz, MD, explains how the addition of novel agents to established chemotherapy regimens could further shift the frontline treatment paradigm for classic Hodgkin lymphoma.

Brentuximab Vedotin Boosts Survival in Adult and AYA Patients with Advanced Hodgkin Lymphoma

July 20th 2022

Ann S. LaCasce, MD, MMSC, explains how bretuximab vedotin has produced a survival benefit in patients with advanced classic Hodgkin lymphoma.

Mosunetuzumab Monotherapy Generates Promising Responses in Relapsed/Refractory Follicular Lymphoma

July 20th 2022

Single-agent mosunetuzumab produced a complete response rate that was greater than what has been observed with historical controls in patients with relapsed/refractory follicular lymphoma who had received at least 2 prior lines of therapy, meeting the primary end point of the expansion portion of the phase 1/2 GO29781 trial.

Pembrolizumab Plus Chemoradiation Misses EFS End Point in Head and Neck Squamous Cell Carcinoma

July 20th 2022

Pembrolizumab plus concurrent chemoradiation followed by pembrolizumab maintenance did not lead to a statistically significant improvement in event-free survival vs concurrent chemoradiation alone in patients with unresected locally advanced head and neck squamous cell carcinoma.

Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL

July 20th 2022

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

Zanubrutinib Showcases Superior PFS Benefit Over BR in Treatment-Naïve CLL/SLL, Including High-Risk Subsets

July 20th 2022

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.